The TheraView electronic portal imaging device (EPID) is an Image-Guided Radiotherapy (IGRT) cancer treatment verification system, designed by Cablon Medical in the Netherlands. The foundation of the TheraView Electronic Portal Imaging System is based on verification, accuracy and flexibility. By bringing radiotherapy images live and on-line, the TheraView EPID reportedly provides radiation oncologists and therapists with a more precise, effective alternative to time-consuming and inconvenient port film. The improved image quality of TheraView can greatly enhance treatment and patient positioning accuracy.
If you enjoy this content, please share it with a colleague
Related Content
June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...
May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...
August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...
June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...
April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...
February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...
December 12, 2019 — Philips and the Regional Medical Center (RMC) announced a strategic 5-year partnership agreement ...
October 22, 2019 — The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) ...
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac System at Dana-Farber/Brigham and Women's Cancer Center. The MRIdian provides for the delivery of radiation therapy to targeted tumors while simultaneously providing continuous magnetic resonance imaging (MRI).
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian announced Ethos therapy, an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.